Organon and Dyax enter into therapeutic antibody alliance

Published: 18-Jul-2007
Sustainability Research & Development

Organon, the human healthcare business unit of Akzo Nobel, has entered into an agreement with Dyax Corp. to discover and develop human therapeutic antibodies for the treatment of auto-immune diseases and cancer.


Organon, the human healthcare business unit of Akzo Nobel, has entered into an agreement with Dyax Corp. to discover and develop human therapeutic antibodies for the treatment of auto-immune diseases and cancer.

Under the terms of the agreement, Dyax will utilise its proprietary phage display technology to identify antibodies directed towards a target identified at Organon's Research Center in Cambridge, MA (US). Dyax will receive licence fees and research funding, as well as milestone payments and royalties on net sales that may result from Organon's clinical development and commercialisation of these antibodies. Financial details were not disclosed.

"Dyax's state-of-the-art phage display technology will help us to strengthen our r&d pipeline of antibody therapies for cancer and auto-immune disorders," said David Nicholson, executive vice-president research & development of Organon.

  • Companies:
  • Nouryon
See more

You may also like

Sustainability

Xceleron and Organon sign microdose study agreement

Read more
UK company Xceleron has signed a collaboration agreement with Organon, the human healthcare business unit of Akzo Nobel, on a three-compound human microdose study focusing on candidate selection for further clinical development.

Trending Articles

  1. You need to be a subscriber to read this article.
    Click here to find out more.
    Parenteral preparations: formulation challenges Parenteral preparations are defined as solutions, suspensions, emulsions for injection or infusion, powders for injection or infusion, gels for injection and implants. They are sterile preparations that are administrated directly into the systemic circulation of humans or animals
  2. COVID-19 still a significant risk for the immunocompromised, study finds AstraZeneca's INFORM study highlights the persistent danger of COVID-19 for the immunocompromised despite the vaccination scheme
  3. Compact process thermostat for efficient temperature control in the lab The Petite Fleur allows for laboratory reactor temperature control between -40 °C to +200 °C with a 480W refrigeration capacity
  4. Miltenyi Biotec and MiLaboratories collaborate to advance next-generation therapies Miltenyi Biotec will commercialise MiLaboratories' RNA kit technology for immune sequencing, facilitating advances in the field of personalised medicine
  5. Abzena launches EpiScreen 2.0 to assist the development of complex biologics and bioconjugates The updated platform delivers an advanced range of immune response measurements, while also providing information on mechanism-of-action and specificity

Upcoming event

ASGCT Annual Meeting 2024

7-11 May, 2024 | Meeting | Portland, OR See all

You may also like

Sustainability

Xceleron and Organon sign microdose study agreement

<p>UK company Xceleron has signed a collaboration agreement with Organon, the human healthcare business unit of Akzo Nobel, on a three-compound human microdose study focusing on candidate selection for further clinical development. </p>
Sustainability

Organon and MRC Technology sign antibody development agreement

<p>Organon, the human healthcare business unit of Akzo Nobel, together with MRC Technology, of London in the UK, have signed a collaborative agreement to develop a humanised antibody for the treatment of certain forms of cancer. </p>
Ingredients

Organon and Medarex form biotherapeutics collaboration

<p>Organon, the human health care business unit of Akzo Nobel, and Medarex are to collaborate on the development of fully human antibody therapeutics for the treatment of cancer and auto-immune disorders.</p>
Sustainability

Entelos and Organon extend research agreement

<p>Entelos, a leading US life sciences company building predictive computer models of human physiology and 'virtual patients' for drug discovery and development, and Organon, the human healthcare business unit of Akzo Nobel have extended their ongoing rheumatoid arthritis (RA) collaboration for a further two years. Financial terms were not disclosed.</p>
Ingredients

Organon partners with Huya to develop Chinese biopharmaceuticals

<p>Organon, the human healthcare business unit of Akzo Nobel, has signed a collaboration agreement with HUYA Bioscience International to search for new, proprietary biopharmaceuticals or pharmaceutical compounds. As part of this collaboration, Organon has acquired an equity interest in HUYA, a biopharmaceutical company focused on developing Chinese biopharmaceutical products. </p>
Manufacturing

Owen Mumford’s near-term and net-zero targets approved by the SBTi

The company's long and short-term initiatives include the reduction of scope 1, 2 and 3 emissions by 42% by 2030, as well as reaching net-zero in greenhouse gas emissions
Research & Development

OGT launches new SureSeq myeloid fusion panel drive myeloid cancer research

The assay enables users to integrate research techniques with a single, streamlined NGS process, expediting the process
Subscribe now